{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T23:13:12Z","timestamp":1788649992427,"version":"build-2803163510"},"reference-count":46,"publisher":"Cambridge University Press (CUP)","issue":"5-6","license":[{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"unspecified","delay-in-days":5372,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur. psychiatr."],"published-print":{"date-parts":[[2005,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Approximately 40\u201370% of treatment-resistant schizophrenic patients fail to benefit from clozapine monotherapy or are partial responders. During the last years several clozapine adjunctive agents have come into clinical practice. This study aims to critically review all published randomized, double-blind, placebo-controlled clinical trials (RCTs) regarding the efficacy and safety of adjunctive agents in clozapine-resistant schizophrenic or schizoaffective patients. A MEDLINE search for RCTs on clozapine adjunctive agents published from January 1980 to February 2004 was conducted. All identified papers were critically reviewed and examined against several methodological features as well as clinical and pharmacological parameters. Eleven trials including 270 patients, partial or non-responders to clozapine, assessed the efficacy of sulpiride, lithium, lamotrigine, fluoxetine, glycine, d-serine, d-cycloserine and ethyl-eicosapentanoate (E-EPA) as clozapine adjuncts. There were eight parallel-group and three crossover trials. The inclusion criteria varied widely. The duration as well as the dosage of clozapine monotherapy were reported adequate in only one trial. Plasma clozapine levels were assessed in only three trials. Main side-effects reported were hypersalivation, sedation, diarrhea, nausea, hyperprolactinaemia. The outcome favored clozapine augmentation with sulpiride, lamotrigine and E-EPA. Lithium was shown to benefit only schizoaffective patients. However, the methodological shortcomings of trials analyzed limit the impact of evidence provided.<\/jats:p>","DOI":"10.1016\/j.eurpsy.2004.12.007","type":"journal-article","created":{"date-parts":[[2005,4,4]],"date-time":"2005-04-04T14:28:51Z","timestamp":1112624931000},"page":"409-415","source":"Crossref","is-referenced-by-count":48,"title":["Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review"],"prefix":"10.1017","volume":"20","author":[{"given":"Vassilis P.","family":"Kontaxakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayotis P.","family":"Ferentinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata J.","family":"Havaki-Kontaxaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris K.","family":"Roukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"S0924933800241370_bib0033","first-page":"133","article-title":"Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia","volume":"55","author":"Potkin","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"S0924933800241370_bib0037","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.171.6.569"},{"key":"S0924933800241370_bib0035","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709183371202"},{"key":"S0924933800241370_bib0040","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000084026.22282.5f"},{"key":"S0924933800241370_bib0042","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.1.2.171"},{"key":"S0924933800241370_bib0041","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050028"},{"key":"S0924933800241370_bib0044","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(03)00524-9"},{"key":"S0924933800241370_bib0028","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000095351.32154.3a"},{"key":"S0924933800241370_bib0030","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(00)00083-9"},{"key":"S0924933800241370_bib0013","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.56.10.950"},{"key":"S0924933800241370_bib0002","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.154.4.1"},{"key":"S0924933800241370_bib0014","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.9.1596"},{"key":"S0924933800241370_bib0016","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.12.2071"},{"key":"S0924933800241370_bib0003","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(02)00354-3"},{"key":"S0924933800241370_bib0026","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1176\/ajp.151.12.1744","article-title":"Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome","volume":"151","author":"Lieberman","year":"1994","journal-title":"Am J Psychiatry"},{"key":"S0924933800241370_bib0043","doi-asserted-by":"publisher","DOI":"10.2174\/0929867043456070"},{"key":"S0924933800241370_bib0021","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.56.1.21"},{"key":"S0924933800241370_bib0038","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(97)80205-2"},{"key":"S0924933800241370_bib0015","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.5.826"},{"key":"S0924933800241370_bib0031","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3956(01)00048-6"},{"key":"S0924933800241370_bib0001","first-page":"484","article-title":"Bromocriptine as adjunctive therapy to clozapine in treatment-resistant schizophrenia","volume":"41","author":"al-Semaan","year":"1996","journal-title":"Can J Psychiatry"},{"key":"S0924933800241370_bib0010","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1176\/ajp.154.9.1243","article-title":"Time to clozapine response in a standardized trial","volume":"154","author":"Conley","year":"1997","journal-title":"Am J Psychiatry"},{"key":"S0924933800241370_bib0024","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800330013001"},{"key":"S0924933800241370_bib0009","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a033463"},{"key":"S0924933800241370_bib0004","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(03)80006-8"},{"key":"S0924933800241370_bib0005","first-page":"1145","article-title":"Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns","volume":"44","author":"Breier","year":"1993","journal-title":"Hosp Community Psychiatry"},{"key":"S0924933800241370_bib0036","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.14.1.86"},{"key":"S0924933800241370_bib0006","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1176\/ajp.153.12.1625","article-title":"Fluoxetine augmentation of clozapine treatment in patients with schizophrenia","volume":"153","author":"Buchanan","year":"1996","journal-title":"Am J Psychiatry"},{"key":"S0924933800241370_bib0008","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(00)00115-9"},{"key":"S0924933800241370_bib0011","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(01)01271-9"},{"key":"S0924933800241370_bib0012","doi-asserted-by":"publisher","DOI":"10.1007\/s002130000503"},{"key":"S0924933800241370_bib0017","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0447.2002.01331.x"},{"key":"S0924933800241370_bib0018","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1176\/ajp.147.4.492","article-title":"Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients","volume":"147","author":"Goff","year":"1990","journal-title":"Am J Psychiatry"},{"key":"S0924933800241370_bib0019","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(98)00367-9"},{"key":"S0924933800241370_bib0020","doi-asserted-by":"publisher","DOI":"10.1007\/BF02246213"},{"key":"S0924933800241370_bib0022","first-page":"395","article-title":"Risperidone as an adjunct to clozapine therapy in chronic schizophrenics","volume":"57","author":"Henderson","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"S0924933800241370_bib0025","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1176\/ajp.152.2.179","article-title":"Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients","volume":"152","author":"Kronig","year":"1995","journal-title":"Am J Psychiatry"},{"key":"S0924933800241370_bib0027","first-page":"30","article-title":"Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations","volume":"27","author":"Llorca","year":"2002","journal-title":"J Psychiatry Neurosci"},{"key":"S0924933800241370_bib0029","first-page":"892","article-title":"Effects of 6 months of clozapine treatment on the quality of life of chronic schizophrenic patients","volume":"41","author":"Meltzer","year":"1990","journal-title":"Hosp Community Psychiatry"},{"key":"S0924933800241370_bib0032","first-page":"231","article-title":"Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients","volume":"148","author":"Perry","year":"1991","journal-title":"Am J Psychiatry"},{"key":"S0924933800241370_bib0034","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.1.145"},{"key":"S0924933800241370_bib0039","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(96)00170-9"},{"key":"S0924933800241370_bib0045","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(98)00279-0"},{"key":"S0924933800241370_bib0046","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1176\/ajp.156.11.1822","article-title":"d-serine added to clozapine for the treatment of schizophrenia","volume":"156","author":"Tsai","year":"1999","journal-title":"Am J Psychiatry"},{"key":"S0924933800241370_bib0023","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.56.1.29"},{"key":"S0924933800241370_bib0007","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a006901"}],"container-title":["European Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924933805000155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924933805000155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924933800241370","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T20:56:06Z","timestamp":1683060966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924933800241370\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":46,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S0924933800241370"],"URL":"https:\/\/doi.org\/10.1016\/j.eurpsy.2004.12.007","relation":{},"ISSN":["0924-9338","1778-3585"],"issn-type":[{"value":"0924-9338","type":"print"},{"value":"1778-3585","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}